Iovance Biotherapeutics Inc (IOVA)

[jondoeuk]

ImmuT Finder is a novel T-cell immunoregulatory target discovery platform https://aacrjournals.org/cancerres/article/83/7_Supplement/4062/723014/Abstract-4062-The-discovery-and-development-of-a

It employs two different screening models, in vitro and in vivo, to simulate a range of challenges that T-cells could encountered within solid tumours. Using CRISPR libraries targeting the entire genome, it identifies a set of candidate hits that potentially regulate T-cell exhaustion and enhance functionality. The selected candidate targets undergo comprehensive functional validation, resulting in development of first-in-class gene knockout T-cell products



GT316 is a next-generation TIL product. Through this platform, key immune regulatory targets in primary T-cells were identified. Subsequently, the KOReTIL platform knocks out the corresponding target genes in TIL. Preclinical in vitro experiments have shown that compared to an unedited first-generation TIL product, GT316 significantly counteracts TIL exhaustion and apoptosis (programmed cell death), promotes TIL proliferation, cytotoxicity, persistence and maintains higher TCR clone diversity. In patient-derived xenograft, GT316, supported by low-dose IL-2, completely eradicate tumour growth. This demonstrates significant advantages of GT316 compared to traditional TIL products. Currently, GT316 is undergoing IIT clinical trials.